YMABEarnings•globenewswire•
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
Sentiment:Negative (30)
Summary
PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 8, 2025 by globenewswire